Hepatitis A Infections and Infestations Hepatitis A
Conditions
Interventions
Subjects were immunised against hepatitis A and subsequently received atorvastatin (40 mg per day) or placebo for a period of 28 days after immunisation.
Sponsors
Geneva University Hospital (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women who were greater than 18 years old were eligible for inclusion if they had neither morbidities nor immunity to hepatitis A
Exclusion criteria
Exclusion criteria: 1. Anti-hepatitis A antibodies greater than 10 IU/l 2. Hypercholesterolemia 3. Hepatitis 4. Myositis 5. Chronic alcohol abuse 6. Pregnant or breast-feeding women 7. Volunteers on drug therapy except oral contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome variable was the achievement of antibody levels greater than 20 IU/l against the hepatitis A virus one month after vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. A secondary outcome variable was the mean log-transformed antibody titre 2. To document the effects of atorvastatin on total blood cholesterol, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), triglycerides, and high-sensitivity C-Reactive Protein (hs-CRP) | — |
Countries
Switzerland
Outcome results
None listed